Michael May

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

13h-index765citations58works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(17), Cancer Genomics and Diagnostics(12), Prostate Cancer Treatment and Research(6), Neuroendocrine Tumor Research Advances(6), Cancer Immunotherapy and Biomarkers(5)

Publications58 total

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
Drugs·2026Open Access
Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma
Nature Genetics·2025· 3 cited
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer
JNCI Journal of the National Cancer Institute·2025· 2 citedOpen Access
Multicenter study of the impact of trial eligibility criteria on enrollment to KRAS G12C inhibitor trials in patients with non-small cell lung cancer.
Journal of Clinical Oncology·2025
CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.
Journal of Clinical Oncology·2025· 1 cited
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation
JCO oncology advances.·2025· 4 citedOpen Access
Cell Division, Life, and Cancer: Novel Fundamental Insights
Critical Reviews in Eukaryotic Gene Expression·2025· 1 cited
Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue
International Journal of Molecular Sciences·2024· 5 citedOpen Access
Abstract A074: Integrated clinical and single-cell profiling analysis reveals cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma
Cancer Research·2024
Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models
Cancer Research·2024
Impact of trial eligibility criteria on enrollment to KRAS<sup>G12C</sup> inhibitor trials in patients with non-small cell lung cancer.
Journal of Clinical Oncology·2024
Recurrence patterns and surveillance strategies in long-term survivors of resected pancreatic cancer.
Journal of Clinical Oncology·2024
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.
Journal of Clinical Oncology·2024· 1 cited
A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors.
Journal of Clinical Oncology·2024· 1 cited
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX
The Oncologist·2024· 4 citedOpen Access
Contribution of neoadjuvant chemotherapy and radiation therapy (intensity-modulated radiation therapy with concurrent chemotherapy versus stereotactic body radiation therapy alone) on tumor volume regression in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A single institution experience.
Journal of Clinical Oncology·2024
Abstract PR05: CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma
Cancer Research·2024· 1 cited
Biochemical progression free and overall survival among Black men with stage <scp>IV</scp> prostate cancer in South Africa: Results from a prospective cohort study
Cancer Medicine·2023· 3 citedOpen Access
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
2023· 4 citedOpen Access
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data
Seminars in Oncology·2023· 3 cited
page 1 of 3Next →

Frequent Co-authors

Gulam A. Manji(18), Alexander G. Raufi(16), Naomi Sender(8), Sarah Sta Ana(7), Susan E. Bates(6), Ilenia Pellicciotta(6), Winston Wong(6), Anjali Saqi(5), Catherine A. Shu(5), Jacob K. Jamison(5), Alissa Michel(5), Anne‐Catrin Uhlemann(4), Ravi Vijayvargia(4), Joseph D. Fondell(4), Connor J. Kinslow(4), Alfred I. Neugut(4), Benjamin Herzberg(4), Samuel Pan(4), Isabelle Ross(4), Mahesh Mansukhani(4)